Valeant Pharmaceuticals shareholder ValueAct reports 16.2% ownership interest

By Lisa Kerner

Charlotte, N.C., Dec. 2 - Investors led by ValueAct Master Fund bought 308,000 shares of Valeant Pharmaceuticals International on Oct. 15 for $17.53 each, according to a schedule 13D/A filed with the Securities and Exchange Commission.

ValueAct also reported that its Sept. 8 stock purchase agreement with Morgan Stanley & Co., Inc. terminated on Friday.

The investors beneficially own approximately 13.24 million shares, or 16.2%, of the Costa Mesa, Calif., specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.